Bardet-Biedl syndrome presenting with early-onset infantile obesity

Patlolla Akhila1, Jyothi Naik1, Thirunavukkarasu Arun Babu2

  • 1Department of Pediatrics, All India Institute of Medical Sciences Mangalagiri (AIIMS), Mangalagiri, Andhra Pradesh, India.

BMJ Case Reports
|January 29, 2026
PubMed

Insights

Bardet-Biedl syndrome (BBS) is a rare genetic disorder. Early-onset obesity in infants can be a key indicator, leading to genetic testing and diagnosis through whole-exome sequencing.

Area of Science:

  • Genetics
  • Pediatrics
  • Endocrinology

Background:

  • Bardet-Biedl syndrome (BBS) is a rare, autosomal recessive genetic disorder.
  • Common BBS features include polydactyly, obesity, retinal degeneration, intellectual disability, kidney issues, and hypogonadism.
  • Infantile obesity is a frequent early clinical finding in BBS.

Purpose of the Study:

  • To report a case of BBS diagnosed in infancy.
  • To highlight the role of early-onset obesity in suspecting syndromic obesity.
  • To emphasize the importance of genetic investigations for BBS diagnosis.

Main Methods:

  • Clinical presentation of an infant with obesity, micropenis, and polydactyly.
  • Whole-exome sequencing to identify genetic mutations.
  • Diagnosis confirmation through homozygous BBS4 gene mutation.

Main Results:

  • An infant presented with syndromic features including infantile obesity and polydactyly.
  • Whole-exome sequencing identified a homozygous BBS4 gene mutation, confirming BBS.
  • The child was managed and discharged, with setmelanotide planned for weight management.

Conclusions:

  • Early-onset obesity is a critical diagnostic clue for genetic syndromes like BBS.
  • Next-generation sequencing is crucial for the definitive diagnosis of BBS.
  • Recognizing infantile obesity aids in timely genetic investigations and management.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.3K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
263
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
631
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
975
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
282
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
181